7.59
0.86 (12.78%)
| Penutupan Terdahulu | 6.73 |
| Buka | 6.69 |
| Jumlah Dagangan | 3,896,277 |
| Purata Dagangan (3B) | 2,613,129 |
| Modal Pasaran | 750,260,928 |
| Harga / Jualan (P/S) | 6.56 |
| Harga / Buku (P/B) | 6.05 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Keuntungan | -16.11% |
| Margin Operasi (TTM) | -466.29% |
| EPS Cair (TTM) | -0.160 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4,900.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 30.33% |
| Nisbah Semasa (MRQ) | 11.00 |
| Aliran Tunai Operasi (OCF TTM) | -20.48 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.60 M |
| Pulangan Atas Aset (ROA TTM) | -6.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -6.91% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | ARS Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.13 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 16.93% |
| % Dimiliki oleh Institusi | 80.28% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |